Tiziana Life Sciences (TLSA) Competitors $2.38 -0.12 (-4.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.41 +0.03 (+1.43%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA vs. NUVB, SION, SNDX, QURE, DNA, IMTX, ANAB, CRON, XERS, and VIRShould you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Nuvation Bio (NUVB), Sionna Therapeutics (SION), Syndax Pharmaceuticals (SNDX), uniQure (QURE), Ginkgo Bioworks (DNA), Immatics (IMTX), AnaptysBio (ANAB), Cronos Group (CRON), Xeris Biopharma (XERS), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry. Tiziana Life Sciences vs. Its Competitors Nuvation Bio Sionna Therapeutics Syndax Pharmaceuticals uniQure Ginkgo Bioworks Immatics AnaptysBio Cronos Group Xeris Biopharma Vir Biotechnology Tiziana Life Sciences (NASDAQ:TLSA) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk. Which has more volatility and risk, TLSA or NUVB? Tiziana Life Sciences has a beta of -0.58, meaning that its share price is 158% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Which has better valuation & earnings, TLSA or NUVB? Tiziana Life Sciences has higher earnings, but lower revenue than Nuvation Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$11.86MN/AN/ANuvation Bio$7.87M95.98-$567.94M-$2.35-0.94 Does the media favor TLSA or NUVB? In the previous week, Nuvation Bio had 6 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 7 mentions for Nuvation Bio and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.89 beat Nuvation Bio's score of 0.44 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nuvation Bio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of TLSA or NUVB? 61.7% of Nuvation Bio shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by company insiders. Comparatively, 29.9% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is TLSA or NUVB more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Nuvation Bio's net margin of -5,534.21%. Tiziana Life Sciences' return on equity of 0.00% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Nuvation Bio -5,534.21%-44.14%-32.97% Do analysts recommend TLSA or NUVB? Nuvation Bio has a consensus price target of $7.17, suggesting a potential upside of 222.82%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryNuvation Bio beats Tiziana Life Sciences on 8 of the 14 factors compared between the two stocks. Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition Export to ExcelMetricTiziana Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$292.12M$3.00B$5.47B$9.53BDividend YieldN/A2.43%4.74%4.08%P/E RatioN/A17.6228.6723.80Price / SalesN/A268.97422.2688.08Price / CashN/A41.9535.4557.96Price / Book59.508.508.275.55Net Income-$11.86M-$55.06M$3.24B$259.03M7 Day Performance27.96%-3.98%-3.63%-4.56%1 Month Performance51.59%9.59%4.40%4.49%1 Year Performance135.64%6.72%25.97%18.05% Tiziana Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences0.8823 of 5 stars$2.38-4.8%N/A+128.8%$292.12MN/A0.008Positive NewsUpcoming EarningsHigh Trading VolumeNUVBNuvation Bio2.2828 of 5 stars$2.55+2.0%$7.17+181.0%-37.4%$850.66M$7.87M-1.0960News CoverageUpcoming EarningsGap UpSIONSionna TherapeuticsN/A$19.85+3.9%$38.50+94.0%N/A$842.78MN/A0.0035Positive NewsLockup ExpirationSNDXSyndax Pharmaceuticals3.5397 of 5 stars$9.57-0.6%$34.10+256.3%-54.6%$828.64M$23.68M-2.48110Upcoming EarningsQUREuniQure2.5575 of 5 stars$14.98-0.9%$37.82+152.5%+83.0%$827.66M$27.12M-3.41500Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionDNAGinkgo Bioworks1.1619 of 5 stars$13.94-0.1%$8.50-39.0%N/A$817.10M$227.04M-1.52640News CoverageGap DownIMTXImmatics2.1547 of 5 stars$6.67+1.7%$14.67+119.9%-45.1%$797.37M$144.15M-39.23260ANABAnaptysBio2.2051 of 5 stars$26.59-1.3%$47.13+77.2%-27.6%$791.51M$91.28M-5.48100News CoverageUpcoming EarningsCRONCronos Group2.3154 of 5 stars$2.06+0.5%N/A-17.0%$790.65M$117.61M15.85450Upcoming EarningsXERSXeris Biopharma3.3716 of 5 stars$5.07+1.0%$6.25+23.3%+121.4%$785.05M$203.07M-16.90290News CoveragePositive NewsUpcoming EarningsShort Interest ↑VIRVir Biotechnology2.8716 of 5 stars$5.48-3.0%$30.25+452.0%-48.3%$781.04M$74.21M-1.30580News CoverageUpcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies NUVB Competitors SION Competitors SNDX Competitors QURE Competitors DNA Competitors IMTX Competitors ANAB Competitors CRON Competitors XERS Competitors VIR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLSA Stock Alerts